IP: Use at a concentration of 1 - 2 μg/ml. WB: Use at a concentration of 1 - 5 μg/ml. Predicted molecular weight: 145 kDa. Optimal dilutions/concentrations should be determined by the end user.
K562 (human bcr/abl protein), ANN-1 (mouse abl protein), HL-60 (human normal abl protein), or NIH 3T3 (mouse normal abl protein) cells
Reacts with both c- and v-abl encoded proteins and inhibits abl protein tyrosine kinase activity. The antibody recognizes v-abl, CML c-bcr/abl p210, human ALL c-bcr/abl p190, human c-abl p145, and mouse c-abl p150 proteins.
Preservative: 0.1% Sodium Azide. Constituents: 0.2% Gelatin, 50mM Sodium phosphate
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.1 mg/ml (Please refer to the vial label for the specific concentration.)
TrpE-abl fusion protein pEX-2.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase,Abl,Chdskm,Jtk7,Bcr/Abl,C-Abl,C-Abl1,P150,V-Abl,Abl1
Cytoplasmic and Nuclear
The c-Abl proto oncogene encodes a protein tyrosine kinase that is located in the cytoplasm and nucleus. In chronic myelogenous leukemia and in a subset of acute lymphoblastic leukemias, the c-Abl proto oncogene undergoes a (9;22) chromosomal translocation producing a novel rearranged chromosome (the Philadelphia chromosome) As the result of the fusion of c-Abl sequences from chromosome 9 to the Bcr gene on chromosome 22. The molecular consequence of this translocation is the generation of a chimeric Bcr/Abl mRNA encoding activated Abl protein tyrosine kinase.